Startseite Kongressberichte & Archiv IASLC 21st World Conference on Lung Cancer

IASLC 21st World Conference on Lung Cancer - Results from the Virtual Presidential Symposium

Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11)

Data from ORIENT-11 show that the addition of sintilimab, an anti-PD-1 antibody, to first-line platinum-based chemotherapy enhances efficacy in patients with locally advanced or metastatic nonsquamous NSCLC. More info


eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients.

Interim results of the randomized, open-label, phase III eXalt3 trial showed that ensartinib excelled over crizotinib in patients with locally advanced or metastatic ALK-positive NSCLC who were naïve to ALK-targeted therapy. More info

 
A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma
 
The randomized phase III CheckMate 743 trial shows the benefit of a chemotherapy-free regimen in patients with previously untreated disease.  More info